Scinai Immunotherapeutics Ltd (SCNI)

$3.45

-0.1

(-2.82%)▲

Market is closed - opens 7 PM, 05 Jun 2024

Performance

  • $3.45
    $3.57
    $3.45
    downward going graph

    0.0%

    Downside

    Day's Volatility :3.36%

    Upside

    3.36%

    downward going graph
  • $1.25
    $13.70
    $3.45
    downward going graph

    63.77%

    Downside

    52 Weeks Volatility :90.88%

    Upside

    74.82%

    downward going graph

Returns

PeriodScinai Immunotherapeutics LtdIndex (Russel 2000)
3 Months
-27.15%
0.0%
6 Months
-51.37%
0.0%
1 Year
-73.3%
0.0%
3 Years
-73.3%
-22.6%

Highlights

Market Capitalization
2.1M
Book Value
- $15.21
Earnings Per Share (EPS)
-16.0
Wall Street Target Price
700.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-27.24%
Return On Equity TTM
0.0%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-9.2M
Diluted Eps TTM
-16.0
Quarterly Earnings Growth YOY
0.26
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Scinai Immunotherapeutics Ltd(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 20189.86%

Current $3.45
Target $700.00

Technicals Summary

Sell

Neutral

Buy

Scinai Immunotherapeutics Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd
-20.94%
-51.37%
-73.3%
-73.3%
-73.3%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.54%
31.88%
92.14%
229.83%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
36.12%
71.83%
234.04%
457.53%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
32.76%
40.6%
124.79%
171.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd
NA
NA
NA
0.0
0.0
-0.27
NA
-15.21
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd
Buy
$2.1M
-73.3%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
229.83%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
457.53%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
171.36%
29.59
39.46%

Company Information

biondvax (nasdaq: bvxv) is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains. biondvax’s technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect.

Organization
Scinai Immunotherapeutics Ltd
Employees
0
CEO
Mr. Amir Reichman M.B.A., M.Sc.
Industry
Miscellaneous

Discover More

FAQs